CONCLUSIONS Poor glycemic control appears to be an independent risk factor for low HDL cholesterol in type 2 diabetes.

CONCLUSIONS Poor glycemic control appears to be an independent risk factor for low HDL cholesterol in type 2 diabetes.

To look farther down the disease spectrum than the analysis in ACCORD, Dr. Aguilar’s group retrospectively examined outcomes for a national cohort of 5,815 ambulatory diabetic patients with established heart failure who were treated in ambulatory clinics at VA medical centers.
During two years of follow-up, mortality rates were:
* 25.0% in the bottom quintile with hemoglobin A1c levels of 6.4% or less.
* 23.0% in the group with A1c levels of 6.5% to 7.1%.
* 17.7% in the middle quintile with glycosylated hemoglobin levels above 7.1% but no more than 7.8%.
* 22.5% in the group with A1c levels of 7.9% to 9.0%.
* 23.2% in the top quartile with hemoglobin A1c levels above 9.0%.
This is must-have information for all the life settlement underwriters out there.

CONCLUSIONS The presence of diabetes was associated with a threefold higher CVD mortality risk, and metabolic syndrome status did not modify this risk. Our findings support the fact that physicians should be aggressive in using CVD risk–reducing therapies in all diabetic patients regardless of metabolic syndrome status.
Please tell me you already knew this…
Longitudinal Analysis of Depressive Symptoms and Glycemic Control in Type 2 Diabetes — Diabetes Care
Small study, interesting findings.
Published online in Diabetologia, three of the four studies found some type of cancer-related association with the long-acting insulin analog.
I have a link to Diabetologia on my sidebar if you are interested in downloading the original studies.
FDA Warning of Byetta Pancreatitis Side Effects Contradicted by New Studies – AboutLawsuits.com
Note where this original post is located. Let’s all wait and see if the FDA changes their position on the drug.
Take Home Lesson:
Consider simply adding the usual recommended debits for CHF to the DM rate.
After all, the HF risk is doubled but not the mortality. And critics of this study question its statistical validity.
Thiazolidinediones such as pioglitazone have been shown to prevent or delay the onset of diabetes when given to patients at high risk of developing diabetes. But other studies have found that the drug class appears to inhibit the development of atherosclerosis.
You must be logged in to post a comment.